MedTrace Logo

Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL

NCT04366128 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-09-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.

Conditions

  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG

CAPA indution immunotherapy

1. Camelirumab 200mg Intravenous injection on day 1. 2. Apatinib 250mg taken orally once daily. 3. Pegaspargase 2000U/m2 Intramuscular injection on day 1.

Sponsors & Collaborators

  • Rong Tao

    lead OTHER

Principal Investigators

  • Rong Tao, MD · Xinhua Hospital, Shanghai Jiaotong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-25
Primary Completion
2021-12-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04366128 on ClinicalTrials.gov